Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarkers of response to PD-1 pathway blockade

28 Feb 2022

Abstract excerpt

The binding of T cell immune checkpoint proteins programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to their ligands allows immune evasion by tumours. The development of therapeutic antibodies, termed checkpoint inhibitors, that bind these molecules or their ligands, has provided a means to release this brake on the host anti-tumour immune response. However, these drugs are costly,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35228677
DOI: 10.1038/s41416-022-01743-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarkers of response to PD-1 pathway blockadePMID 35228677Read ↗

Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1.Semantic proximity Read ↗

Advances and prospects of biomarkers for immune checkpoint inhibitorsSemantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.Semantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy.Semantic proximity Read ↗

Biomarker for personalized immunotherapySemantic proximity Read ↗

Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review).Semantic proximity Read ↗

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapySemantic proximity Read ↗

Cancer Immunotherapy Biomarkers of Response and Toxicity; Current Limitations and Future PromiseSemantic proximity Read ↗

PD-L1 as a biomarker in NSCLC: challenges and future directionsSemantic proximity Read ↗

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.